Summary of Conference Call Records Industry or Company Involved - **Li Min Co., Ltd.**: Engaged in the research, production, and sales of pesticides and veterinary drugs - **Angli Kang**: Focused on the production of innovative and generic pharmaceuticals, including pet medications Core Points and Arguments Li Min Co., Ltd. - The company is investing in a new energy project for solid-state batteries, aiming to produce 20,000 tons/year of LiFSI, which is expected to contribute an additional gross profit of 600-800 million yuan [3][4] - The company is collaborating with Chengdu Green Xinnuo and Shanghai Zhisheng Yougu to develop RNA and small peptide biopesticides, enhancing its synthetic biology capabilities [3] - The demand for the company's products is anticipated to increase due to the supply tightness of chlorantraniliprole, which overlaps with its existing products [3] - The company has signed a cooperation agreement with a technical team led by Professor Guan Shiyou, focusing on the full chain technology of new energy electrolytes [3] Angli Kang - The company is involved in the production of chemical raw materials, chemical formulations, and veterinary drugs, with a focus on various therapeutic areas including anti-infectives and cardiovascular drugs [5] - Angli Kang has a pipeline of approximately 50 new generic drug varieties expected to be launched, supported by significant R&D investments over the past few years [5] - The company is shifting its R&D strategy towards modified new drugs and innovative drugs, particularly in the areas of cardiovascular and pain management [5] - The pet medication project initiated in 2021 targets various health issues in pets, including pain, colds, and digestive problems [5] Other Important but Possibly Overlooked Content - The overall market showed a mixed performance with the ChiNext index leading the gains, while the Shanghai Composite Index managed to stay above 3400 points [1] - Institutional participation decreased slightly, with 17 stocks having net buy/sell amounts exceeding 10 million yuan, indicating a cautious market sentiment [2] - The performance of various sectors was noted, with rare earth permanent magnet stocks and automotive parts showing strong gains, while nuclear power stocks faced adjustments [1] - The projected increase in LiFSI usage in new battery technologies, particularly in the 4680 battery, is expected to drive demand significantly, with estimates suggesting a potential increase in usage from 0.5-2% to as high as 15% [4]

Core Viewpoint - The company has announced a cash dividend of 0.06 yuan per share, approved at the 2024 annual general meeting held on May 23, 2025 [1][2]. Dividend Distribution Plan - The dividend distribution is based on the total share capital minus shares held in the company's repurchase account, with a total of 399,441,300 shares eligible for distribution [2][4]. - The total cash dividend to be distributed amounts to 23,966,478.00 yuan (including tax) [2]. - The company will not issue bonus shares or capital reserves, and the distribution will only involve cash dividends [2][4]. Implementation Method - Cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited Shanghai Branch to shareholders registered by the end of the trading day on the record date [5]. - Shareholders who have completed designated transactions can receive their cash dividends on the payment date, while those who have not will have their dividends held until they complete the necessary transactions [5]. Taxation Information - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 0.06 yuan per share [8]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but tax will be calculated and deducted upon the sale of shares [8]. - Qualified Foreign Institutional Investors (QFIIs) will have a 10% corporate income tax withheld, resulting in a net distribution of 0.054 yuan per share [9].

根据市场公开信息及6月11日披露的机构调研信息，知名私募正圆投资近期对2家上市公司进行了调研， 相关名单如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 调研纪要：四创电子2024年实现营收16.03亿元，净利润-24,588万元。公司聚焦低空飞行保障和低空安 全防控，布局低空软件、系统级产品及装备，构建四大应用场景。未来将做强'一核两翼新动能'产业， 扩大雷达产品谱系，拓展国防军工等领域，融合低空经济。2025年营业收入预算力争实现20亿元，增长 集中在感知基础和感知产品领域。华耀电子电源应用于多个领域，包括机载预警、火控等。公司积极开 拓各地聚变项目，包括上海、成都等地。多功能机动反无车提供目标防护与指挥通信解决方案。公司在 合肥积极推进低空经济项目，未来将拓展至其他地区。 机构简介： 深圳正圆投资2015年成立于深圳前海自贸区，并于当年获得私募证券投资基金牌照。正圆拥有专业的投 研团队，丰富的投资经验，完善的风险管理制度。 立足于中国经济结构转型升级，服务于中国实体经 济发展。依赖团队专业的投研能力，致力于成为社会资本与优 ...

浙江天册律师事务所 关于 浙江九洲药业股份有限公司 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于 浙江九洲药业股份有限公司 法律意见书 编号：TCYJS2025H0852 号 致：浙江九洲药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江九洲药业股份有限公司（以 下简称"九洲药业"或"公司"）的委托，就公司 2024 年度利润分配方案所涉及 的差异化权益分派（以下简称"本次差异化权益分派"）相关事宜，根据《中华人 民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公司法》（以 下简称"《公司法》"）、《上市公司股份回购规则（2025 修订）》（以下简称 "《回购规则》"）和《上海证券交易所上市公司自律监管指引第 7 号——回购股 份（2025 年 3 月修订）》（以下简称"《自律监管指引第 7 号》"）等有关法律、 法规和有关规范性文件，出具本法律意见书。 第一部分 声明事项 为出具本法律意见书，本所及本所律师声明如下： 一、为出具本法律意见书 ...

Group 1 - Libet has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds, valid for 12 months [1] - Dinglong plans to acquire an additional 8% stake in its subsidiary, increasing its ownership from 91.35% to 99.35% for a total price of 240 million yuan [1] - Longyuan Donggu has been designated as a supplier for a major automotive project, with an expected total sales amount of 450 to 500 million yuan over five years [14] Group 2 - Luoniushan reported a sales revenue of 100 million yuan in May, a year-on-year decrease of 11.45% [2] - Baoming Technology has secured a loan commitment of up to 7 million yuan for stock repurchase [2] - Xinhua Pharmaceutical has received approval for the listing of a new chemical raw material used in treating chronic heart failure and hypertension [3] Group 3 - China Minmetals announced a new contract amount of 396 billion yuan for the first five months of the year, a decrease of 22.2% year-on-year [7] - Zhongbei Communication's application for a specific stock issuance has been accepted by the Shanghai Stock Exchange [8] - Rongfa Nuclear Power plans to issue bonds not exceeding 1 billion yuan to repay debts and supplement working capital [9] Group 4 - Phoenix Optical plans to invest 8.5 million USD to establish a wholly-owned subsidiary in Vietnam for manufacturing optical products [11] - Xiamen Airport reported a passenger throughput of 2.4752 million in May, a year-on-year increase of 8.34% [12] - Weilan Biological has received a new veterinary drug registration certificate for a product aimed at treating canine allergies and inflammation [13] Group 5 - Shouxiangu has completed the registration of a health food product that claims to enhance immunity [13] - Xingye Yinxin's subsidiary has passed a resource reserve verification report, confirming significant mineral reserves [16] - Shaanxi Construction has won two major projects with a total contract value exceeding 2.8 billion yuan [18] Group 6 - Huari received a cash dividend of 50 million yuan from its subsidiary [20] - Zhongchu's deputy general manager has resigned due to governance arrangements [21] - Kexin Pharmaceutical's core product has received breakthrough therapy designation from the National Medical Products Administration [39]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of Sacubitril/Valsartan Sodium, which is indicated for adult patients with heart failure with reduced ejection fraction, aimed at reducing the risk of cardiovascular death and hospitalization due to heart failure [1] Company Summary - The approved drug, Sacubitril/Valsartan Sodium tablets, is specifically for adult patients suffering from chronic heart failure with reduced ejection fraction [1] - The anticipated sales revenue for Sacubitril/Valsartan Sodium tablets in Chinese public medical institutions is approximately RMB 4.9 billion in 2024 [1]

Group 1: Capital Expenditure Cycle Analysis - The capital expenditure (CAPEX) cycle is a dominant driver of industry cycles in China, influencing the relationship between CAPEX, price-to-book (PB) ratio, and return on equity (ROE) [4] - The CAPEX cycle is divided into three stages: Stage 1 (oversupply leads to declining ROE and poor market performance), Stage 2 (declining CAPEX results in rising free cash flow and market rebound), and Stage 3 (supply-side clearing leads to improved ROE and better market performance) [4][14][15] - The PB-ROE model indicates significant investment value in Stage 2 (low PB and improving ROE) and Stage 3 (reasonable PB and steadily rising ROE) [16] Group 2: Market and Industry Comparisons - In Q4 2024 and Q1 2025, the overall capital expenditure of A-share companies (excluding finance and real estate) is contracting, while free cash flow is improving [20] - The median CAPEX/depreciation ratio for secondary industries decreased from 1.35 to 1.29, while the median free cash flow/equity ratio increased from 4.4% to 4.8% [21] - The proportion of secondary industries with free cash flow greater than 0 has significantly increased, indicating a positive trend in cash flow [21][24] Group 3: Sector-Specific Insights - The consumer sector shows overall CAPEX contraction and slight decline in free cash flow, with CAPEX levels below market averages and free cash flow above market averages [26] - The advanced manufacturing sector also experiences CAPEX contraction, while free cash flow shows slight improvement [4][26] - Eight industries within the consumer sector are highlighted as potential investment opportunities based on supply-side improvements [4][26]

| 连板数 | 晋级率 | | 2025-6-11 | | --- | --- | --- | --- | | 5进6 | 1/1=100% | 易明医药（实控人变更+医药） | | | 3 #4 | 2/3=66% | 昂利康(创新药) | | | 2进3 | 3/8=37% | 北矿科技(稀土永磁) | | | | | 粤传媒(体育) | | | 1讲2 | 4/32=12% | 曲江文旅(长安的荔枝) | | | | | 新日股份 (两轮车) | | | 其他涨停 | | 元降雅图9天5板 (稳定币+IP经济) | | | | | 南京商旅3天2板 (江苏文旅) | | 今日共51股涨停，连板股总数10只，其中三连板及以上个股6只，上一交易日共13只连板股，连板股晋级率46.15%（不含ST股、退市股）。个股方面，全市 场超3400只个股上涨，但高位股走弱，丽人丽妆、金时科技、联化科技、均瑶健康跌停，百利电气、海辰药业等跌超9%。共创草坪断板，市场连板高度降 至6板的易明医药。板块方面，汽配板块开盘大涨，英利汽车、西上海、迪生力等十余股涨停，消息面上，比亚迪、东风汽车、中国一汽和广汽集团等车企 纷纷宣布 ...

导读：医药，这个曾经被寄予厚望的"黄金赛道"，在过去几年遭遇了最漫长的"寒冬"。但是在医药基金的冬天中，优秀 的医药投资团队并没有"冬眠"。当行业进入反转后，机会一定是留给有准备的人。 2025年，A股市场呈现了比较明显的结构性行情。截至6月9日，沪深300指数下跌了-1.26%，但基金业绩的表现出现了 很大差异，这种差异背后主要来自基金经理的阿尔法能力。 以今年的医药板块为例，不少医药基金表现突出，让大家"误认为"今年是一次医药板块的整体性牛市。但是，根据Wind 的数据统计，医药生物板块今年的涨幅为10.29%，并不突出 （数据来源：Wind；数据截至：2025年6月9日） 。 数据来源：Wind；数据截至：2025年6月9日 政策产业共振， 医药投资窗口全面开启 当下的医药投资领域，正迎来政策东风、产业质变、全球共振与业绩兑现的多重利好叠加期，创新药赛道的投资价值正 以肉眼可见的速度迸发。 从政策维度看，顶层设计正为创新药产业铺设高速跑道。《全链条支持创新药发展实施方案》政策的落地，犹如为行业 注入"强心剂"——发展创新药关系医药产业发展，关系人民健康福祉。要全链条强化政策保障，统筹用好价格管理、医 保 ...

Group 1 - The non-bank financial sector saw a net inflow of over 38 billion yuan, indicating strong investor interest [1][2] - The securities and transportation equipment sectors also experienced significant net inflows of 32.65 billion yuan and 29.20 billion yuan, respectively [2] - In contrast, the pharmaceutical, basic chemicals, and new energy sectors faced substantial net outflows, with pharmaceuticals leading at -28.82 billion yuan [2] Group 2 - The top stock by net inflow was N影石, attracting 17.03 billion yuan, with a net inflow rate of 49.54% [3] - Other notable stocks with significant net inflows included 东方财富 (6.37 billion yuan), 比亚迪 (6.34 billion yuan), and 兴业证券 (6.01 billion yuan) [3] - On the sell side, 联化科技 experienced the highest net outflow at -8.61 billion yuan, followed by 中科曙光 (-7.23 billion yuan) and 乐山电力 (-3.66 billion yuan) [4]